Recent Trends in Collaborative, Open Source Drug Discovery

Roy, Anuradha

doi:10.2174/2210289201102010130

Cited by 6 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the mid-and long-term, repurposing strategy of failures may yet be found to enhance the opportunity in out-licensing. A major focus for drug repurposing is to re-pursue drug candidates that did not succeed in advanced clinical trials, for reasons other than safety, for potential new therapeutic applications (Roy et al 2011). Drug repurposing is cost-effective as these compounds have the necessary safety profile, and further investigation requires identification of new therapeutic indications (Roy et al 2011).…”

Section: Discussionmentioning

confidence: 99%

Outbound open innovation in bio-pharmaceutical out-licensing

McNamara

McLoughlin

2015

Technovation

View full text Add to dashboard Cite

a b s t r a c tOur study investigates the outbound open innovation of firms engaged in technological venturing. Leveraging insights from the sociology theory and innovation literatures, we clarify whether social status helps entrepreneurial ventures overcome market imperfection and information asymmetry in outlicensing and illustrate the importance of specific aspects of social status building in this context. We also examine the effect of failure experiences on out-licensing. We take a dynamic view of desorptive capacity by studying an entrepreneurial venture's learning process, both internally, in terms of its own technology trajectory, and externally, through inter-organizational alliances. We apply a negative binomial model to our novel panel of 180 firms studied over an 18-year period with controls for stocks of clinical development activities, patenting and prior licensing activities. Empirical analysis enables us to observe the impact which the firms' technological and development status, reputation and desorptive capacity exert upon out-licensing volume. Prior outbound open innovation studies do not account for the heterogeneity of technology and R&D success and failure experiences observed in our study. We also demonstrate the contingency effect of external learning from alliances during the building-up of a firm's desorptive capacity, or the way in which the number of co-authoring partners in scientific publications negatively moderates the positive effect of the number of commercial alliances on the volume of its outlicensing deals. Our findings contribute to the understanding of external knowledge exploitation and complement important aspects of the literatures on outbound open innovation and desorptive capacity, offering empirically rich insights for bio-pharmaceutical firms into the drivers behind volumes of outlicensing deals.Crown

show abstract

Section: Discussionmentioning

confidence: 99%

Outbound open innovation in bio-pharmaceutical out-licensing

McNamara

McLoughlin

2015

Technovation

View full text Add to dashboard Cite

show abstract

“…This gives an edge to the academic scientists in identifying and validating novel molecular targets for various diseases, developing assays and to some extent, in probe discovery. In general, the mission of the industrial sector is not set up to do comprehensive basic research on biological targets, which warrants active collaboration between industry and academia [Roy et al 2011].…”

Section: "Knowledge Cloud" Inflowsmentioning

confidence: 99%

“…It also provides on-line platform with working papers, articles, and post documents 1 . Another form of such a collaboration in research is NIH Roadmap Initiative in the USA and its European counterpart -EU-OPENSCREEN [Roy et al 2011], which resulted in the emergence of probe discovery in Academia, as well as high throughput screening (HTS) centers harbored in universities all over the USA and compound libraries like PubChem [Roy et al 2011]. It is worth noticing here that the described "openness" concept in the sphere of pharmaceutical industry is not the openness in the meaning of public good.…”

Section: "Knowledge Cloud" Inflowsmentioning

confidence: 99%

“…It is noteworthy that they represent mainly "the knowledge cloud" suppliers with the very basic research needed on the pre-discovery or early discovery stage. There may be mentioned Eli Lilly-PD2 Initiative [https://openinnovation.lilly.com/dd], Merck-Sage Bionetworks [http://sagebase.org/], GSK-caBIG Collaboration, Structural Genomic Consortium and many others [Roy et al 2011].…”

Section: Knowledge Transition From Cloud To Firmmentioning

confidence: 99%

See 1 more Smart Citation

Knowledge in Open Innovation Process on an Example of Pharmaceutical Industry

Pohulak-Żołędowska¹,

Żabiński²,

Sosnowski³

2017

Prace Naukowe Uniwersytetu Ekonomicznego we Wrocławiu

View full text Add to dashboard Cite

The innovation models develop over time, due to market and industry needs. As the main "product" of knowledge economy, innovations (as a concept) are symbolic goods, founded in symbols, not in atoms. This notion causes some consequences typical for information goods, like ease of replication or exchange, zero-marginal replication costs and cheap storage. On the other hand, there is a growing innovation production cost and uncertainty and risk of innovation activity that discourage companies from being innovative. Open innovation model shows the knowledge flows in the "inner" and "outer" sphere of the innovation process. The knowledge has been showed in some aspects: as private good, public good and also as "the commons". The transition spheres have been showed too. Opening the innovation process is addressed to the costly and risky projects that cause risk aversion amongst entrepreneurs, but without which useful products might have never been produced. The goal of the article is to show the knowledge flow and knowledge transition between innovation actors, its "common" nature and the trial to show the value added in the open innovation process. Methods used are literature and data analysis as well as case study.

show abstract